Literature DB >> 11896751

Acceleration of chromosomal instability of BRCA1-associated hereditary breast cancers by p53 abnormality.

Yasuo Miyoshi1, Kyoko Iwao, Noriko Ikeda, Chiyomi Egawa, Shinzaburo Noguchi.   

Abstract

Chromosomal instability (CIN) of BRCA1-associated hereditary breast cancers was studied by fluorescence in situ hybridization of chromosomes 1, 11, and 17. CIN values (the percentage of cells with a nonmodal chromosome) were obtained for each of three chromosomes, and their average was finally used as the CIN value of the sample. BRCA1-associated tumors showed a significantly (p = 0.0089) higher CIN value than normal breast tissues (24.3 +/- 4.3, n = 7, vs. 9.2 +/- 1.1, n = 6, mean +/- SE). In addition, BRCA1-associated tumors with positive p53 immunostaining showed a significantly (p = 0.0018) higher CIN value than those with negative p53 immunostaining (35.7 +/- 3.5, n = 3, vs. 15.8 +/- 1.3, n = 4). These results demonstrate that a loss of BRCA1 function results in the growth of breast cancers with CIN, and this phenotype is further accelerated by p53 abnormality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896751     DOI: 10.1046/j.1524-4741.2002.08201.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  3 in total

1.  Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.

Authors:  Laura De Vargas Roditi; Franziska Michor
Journal:  J Theor Biol       Date:  2010-12-29       Impact factor: 2.691

2.  Chromosome instability and benefit from adjuvant anthracyclines in breast cancer.

Authors:  A F Munro; C Twelves; J S Thomas; D A Cameron; J M S Bartlett
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

3.  Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group.

Authors:  Christoph E Heilig; Harald Löffler; Ulrich Mahlknecht; Johannes W G Janssen; Anthony D Ho; Anna Jauch; Alwin Krämer
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.